" class="no-js "lang="en-US"> CamDiab - Medtech Alert
Thursday, April 18, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
CamDiab | Pharmtech Focus

CamDiab

About CamDiab

CamDiab

CamAPS® FX: The advanced, adaptive, hybrid closed-loop app that automatically adjusts insulin delivery via an insulin pump based on sensor glucose readings. Suitable from 1 years of age, including pregnancy, for use in people living with type 1 diabetes.

Related Story

Industry News

 Abbott

Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes

April 28 2022

Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize […]